VRDN 23.27 Viridian Therapeutics, Inc.
| Range: | 10.925-24.75 | Vol Avg: | 1492135 | Last Div: | 0 | Changes: | 1.63 |
| Beta: | 1.09 | Cap: | 1.80B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jun 18 2014 | Empoloyees: | 94 | ||
| CUSIP: | 92790C104 | CIK: | 0001590750 | ISIN: | US92790C1045 | Country: | US |
| CEO: | Mr. Stephen F. Mahoney J.D., MBA | Website: | https://www.viridiantherapeutics.com | ||||
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Stock Details
VRDN 44
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
Gregory Renza·Fri Sep 13 2024
RBC Capital
VRDN 38
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
Serge Belanger·Wed Sep 11 2024
Needham
VRDN 22
Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
Kalpit Patel·Wed Sep 11 2024
B.Riley Financial
VRDN 40
Viridian Therapeutics price target raised to $40 from $33 at Stifel
Alex Thompson·Tue Sep 10 2024
Stifel Nicolaus
VRDN 56
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
Julian Harrison·Tue Sep 10 2024
BTIG
VRDN 25
Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Richard Law·Wed Aug 14 2024
Goldman Sachs
VRDN 35
RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
Gregory Renza·Tue Jun 11 2024
RBC Capital
VRDN 46
BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Julian Harrison·Tue Jun 11 2024
BTIG
VRDN 29
Viridian Therapeutics initiated with an Outperform at Wolfe Research
Andy Chen·Mon Jun 10 2024
Wolfe Research
VRDN 23
Viridian Therapeutics initiated with a Buy at Goldman Sachs
Richard Law·Thu Jun 06 2024
Goldman Sachs
VRDN 31
Viridian Therapeutic (VRDN) PT Lowered to $31 at Oppenheimer
Leland Gershell·Thu May 09 2024
Oppenheimer
VRDN 27
Viridian Therapeutic (VRDN) PT Lowered to $27 at H.C. Wainwright
Douglas Tsao·Thu May 09 2024
H.C. Wainwright
VRDN 20
B.Riley Downgrades Viridian Therapeutic (VRDN) to Neutral
Kalpit Patel·Thu May 09 2024
B.Riley Financial
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow